Paper33059819
Imaging for Response Assessment in Cancer Clinical Trials.
Sorace AG and 12 others. Semin Nucl Med, 2020. Cited by 35 papers, by iCite.
Cite this record
ConductScience Library. Imaging for Response Assessment in Cancer Clinical Trials. Papers, record 33059819. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33059819
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Clinical Trials as Topic | Major topic |
| Neoplasms | Major topic |
| Humans | |
| Diagnostic Imaging | |
| Treatment Outcome |
Source PubMed
Grants10
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| U01 CA225427 | NCI NIH HHS | United States | U01CA225427 | PubMed and NIH | NIH RePORTER |
| U01 CA142565 | NCI NIH HHS | United States | U01CA142565 | PubMed and NIH | NIH RePORTER |
| R01 CA207290 | NCI NIH HHS | United States | R01CA207290 | PubMed and NIH | NIH RePORTER |
| TL1 TR003106 | NCATS NIH HHS | United States | TL1TR003106 | PubMed and NIH | NIH RePORTER |
| U24 CA226110 | NCI NIH HHS | United States | U24CA226110 | PubMed and NIH | NIH RePORTER |
| R01 CA240589 | NCI NIH HHS | United States | R01CA240589 | PubMed and NIH | NIH RePORTER |
| R01 CA186193 | NCI NIH HHS | United States | R01CA186193 | PubMed and NIH | NIH RePORTER |
| U01 CA174706 | NCI NIH HHS | United States | U01CA174706 | PubMed and NIH | NIH RePORTER |
| DP2 CA261453 | NCI NIH HHS | United States | DP2CA261453 | PubMed | NIH RePORTER |
| R00 CA215604 | NCI NIH HHS | United States | R00CA215604 | PubMed and NIH | NIH RePORTER |
References123
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28522740 | Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer. | J Nucl Med | 2017 | https://conductscience.org/library/papers/28522740 | PubMed |
| 2 | 31614001 | Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. | Prostate | 2020 | https://conductscience.org/library/papers/31614001 | PubMed |
| 3 | 24892406 | Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. | Nat Commun | 2014 | https://conductscience.org/library/papers/24892406 | PubMed |
| 4 | 28928380 | Predictors of responses to immune checkpoint blockade in advanced melanoma. | Nat Commun | 2017 | https://conductscience.org/library/papers/28928380 | PubMed |
| 5 | 28749202 | Abbreviated breast MRI for screening women with dense breast: the EA1141 trial. | Br J Radiol | 2018 | https://conductscience.org/library/papers/28749202 | PubMed |
| 6 | 23882093 | Apparent diffusion coefficient and beyond: what diffusion MR imaging can tell us about tissue structure. | Radiology | 2013 | https://conductscience.org/library/papers/23882093 | PubMed |
| 7 | 28872549 | 89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. | Clin Nucl Med | 2017 | https://conductscience.org/library/papers/28872549 | PubMed |
| 8 | 30179110 | Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial. | Radiology | 2018 | https://conductscience.org/library/papers/30179110 | PubMed |
| 9 | 32118298 | Relevance of liver surface nodularity for preoperative risk assessment in patients with resectable hepatocellular carcinoma. | Br J Surg | 2020 | https://conductscience.org/library/papers/32118298 | PubMed |
| 10 | 19097774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 11 | 27655428 | Inter-observer agreement improves with PERCIST 1.0 as opposed to qualitative evaluation in non-small cell lung cancer patients evaluated with F-18-FDG PET/CT early in the course of chemo-radiotherapy. | EJNMMI Res | 2016 | https://conductscience.org/library/papers/27655428 | PubMed |
| 12 | 30755811 | Antibody and fragment-based PET imaging of CTLA-4+ T-cells in humanized mouse models. | Am J Cancer Res | 2019 | https://conductscience.org/library/papers/30755811 | PubMed |
| 13 | 28082434 | 89Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma. | J Nucl Med | 2017 | https://conductscience.org/library/papers/28082434 | PubMed |
| 14 | 29975116 | Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CT. | AJR Am J Roentgenol | 2018 | https://conductscience.org/library/papers/29975116 | PubMed |
| 15 | 29570895 | Repeatability, reproducibility, and accuracy of quantitative mri of the breast in the community radiology setting. | J Magn Reson Imaging | 2018 | https://conductscience.org/library/papers/29570895 | PubMed |
| 16 | 23572497 | Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab. | J Nucl Med | 2013 | https://conductscience.org/library/papers/23572497 | PubMed |
| 17 | 28461564 | Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. | Cancer Res | 2017 | https://conductscience.org/library/papers/28461564 | PubMed |
| 18 | 30973773 | Current Imaging Techniques for Noninvasive Staging of Hepatic Fibrosis. | AJR Am J Roentgenol | 2019 | https://conductscience.org/library/papers/30973773 | PubMed |
| 19 | 28423698 | Parameters of simultaneous 18F-FDG-PET/MRI predict tumor stage and several histopathological features in uterine cervical cancer. | Oncotarget | 2017 | https://conductscience.org/library/papers/28423698 | PubMed |
| 20 | 27865762 | Tumor-targeted nanomedicines for cancer theranostics. | Pharmacol Res | 2017 | https://conductscience.org/library/papers/27865762 | PubMed |
Cited by29
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 35 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42938211 | Optimizing Portal Venous Phase Acquisition Quality of Contrast-Enhanced CT in Oncology. | Diagnostics (Basel) | 2026 | https://conductscience.org/library/papers/42938211 | PubMed |
| 42505404 | Rewiring Tumor Lifelines: Translating Hypoxia- and Pseudohypoxia-Driven Angiogenesis into Therapeutic Breakthroughs. | Cells | 2026 | https://conductscience.org/library/papers/42505404 | PubMed |
| 42147365 | Artificial intelligence empowered biomaterials for cancer therapy: From rational design to clinical translation. | Chin J Cancer Res | 2026 | https://conductscience.org/library/papers/42147365 | PubMed |
| 42063134 | Prediction of relapsed/refractory primary central nervous system lymphoma using pre-chemotherapy ITSS grade on SWI and pre-/post-chemotherapy ADC parameters on DWI. | Cancer Imaging | 2026 | https://conductscience.org/library/papers/42063134 | PubMed |
| 41150754 | Monitoring Pharmacological Treatment of Breast Cancer with MRI. | Curr Issues Mol Biol | 2025 | https://conductscience.org/library/papers/41150754 | PubMed |
| 40888645 | Modeling the effects of combination immunotherapy on triple-negative breast cancer in syngeneic mice from PET imaging of CD4+ and CD8+ cells. | Math Med Biol | 2025 | https://conductscience.org/library/papers/40888645 | PubMed |
| 40647404 | Current Approaches of Nuclear Molecular Imaging in Breast Cancer. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40647404 | PubMed |
| 40635706 | Potential mechanisms and clinical applications of static magnetic field therapy in glioma. | Front Neurol | 2025 | https://conductscience.org/library/papers/40635706 | PubMed |
| 40585764 | Harnessing Biomarker Activatable Probes for Early Stratification and Timely Assessment of Therapeutic Efficacy in Cancer. | Exploration (Beijing) | 2025 | https://conductscience.org/library/papers/40585764 | PubMed |
| 40392709 | Comparison of Progression-Free Survival in Familial Non-Medullary Thyroid Cancer and Sporadic Differentiated Thyroid Cancer Patients. | Thyroid | 2025 | https://conductscience.org/library/papers/40392709 | PubMed |
| 40121305 | Characterizing SSTR2 expression and modulation for targeted imaging and therapy in preclinical models of triple-negative breast cancer. | Sci Rep | 2025 | https://conductscience.org/library/papers/40121305 | PubMed |
| 40050894 | Oxygen-delivery nanoparticles enhanced immunotherapy efficacy monitored by granzyme B PET imaging in malignant tumors. | J Nanobiotechnology | 2025 | https://conductscience.org/library/papers/40050894 | PubMed |
| 40003667 | Systematic Review: AI Applications in Liver Imaging with a Focus on Segmentation and Detection. | Life (Basel) | 2025 | https://conductscience.org/library/papers/40003667 | PubMed |
| 39941318 | The Value of MRI and Radiomics for the Diagnostic Evaluation of Thyroid-Associated Ophthalmopathy. | Diagnostics (Basel) | 2025 | https://conductscience.org/library/papers/39941318 | PubMed |
| 38338997 | In Vitro MRS of Cells Treated with Trastuzumab at 1.5 Tesla. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38338997 | PubMed |
| 37931781 | Investigating tumor-host response dynamics in preclinical immunotherapy experiments using a stepwise mathematical modeling strategy. | Math Biosci | 2023 | https://conductscience.org/library/papers/37931781 | PubMed |
| 37626587 | Combination Therapy with Trastuzumab and Niraparib: Quantifying Early Proliferative Alterations in HER2+ Breast Cancer Models. | Biomedicines | 2023 | https://conductscience.org/library/papers/37626587 | PubMed |
| 37540134 | Discrepant Assessments of Progressive Disease in Clinical Trials between Routine Clinical Reads and Formal RECIST 1.1 Interpretations. | Radiol Imaging Cancer | 2023 | https://conductscience.org/library/papers/37540134 | PubMed |
| 37310427 | Patlak-Ki derived from ultra-high sensitivity dynamic total body [18F]FDG PET/CT correlates with the response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer patients. | Eur J Nucl Med Mol Imaging | 2023 | https://conductscience.org/library/papers/37310427 | PubMed |
| 36828382 | Evaluation of Apparent Diffusion Coefficient Repeatability and Reproducibility for Preclinical MRIs Using Standardized Procedures and a Diffusion-Weighted Imaging Phantom. | Tomography | 2023 | https://conductscience.org/library/papers/36828382 | PubMed |
Genes23
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33059819
GET https://conductscience.org/api/papers/v1/33059819/references?page=2